Central serous retinopathy (CSR) is a heterogeneous disease with different phenotypes. Multimodal imaging is one way to understand more about the pathogenesis of the disease, and can be used to guide treatment.
CSR is highly prevalent, especially in Eastern countries. Different treatments have been suggested but none of them have demonstrated universal efficacy for the different phenotypes of the disease.
Giuseppe Querques, MD, presented two cases. The first was a case of an acute form of CSR. The patient was followed for three months with no intervention. There was no spontaneous resolution, so the patient was treated with eplerenone, a mineralocorticoid receptor (MR) antagonist, for three months.
The OCTA showed the appearance of choriocapillaris, and the ICG disclosed the presence of a hotspot that was interpreted as an actively leaking stage of the disease.
Giuseppe Querques, MD, is a consultant to Alimera Sciences, Allergan, Bayer Healthcare Pharmaceuticals, Carl Zeiss Meditec. Heidelberg Engineering, Novartis Pharmaceuticals Corp., and Sandoz.